Category Archives: Stem Cell Treatment

CellVoyant secures 7.6 million seed funding to develop stem cell therapies with AI – BioPharma-Reporter.com

Led by Octopus Ventures, with participation from Horizons Ventures, Verve Ventures, and Air Street Capital, this funding marks the first stage in commercialising CellVoyant's AI and imaging platforms.

The company aims to enable the cost-effective and rapid development of novel cell therapies. The proceeds from this funding round will be used to increase headcount, expand laboratory and experimental infrastructure, and support R&D.

Rafael E. Carazo Salas, CEO and founder of CellVoyant, said: Cell therapies have the potential to revolutionise the way we treat diseases that affect millions of people every year. By combining the latest advances in AI and live cell imaging, we can help bring these transformative treatments to the market quickly, reliably, and cost-effectively. Todays milestone validates the potential of our approach and will help us to accelerate our R&D capabilities.

Stem cells unlock a range of treatment possibilities that have not previously been available to patients. Current treatment options act on the bodys existing cells, while stem cells can develop into many different cell types in the body - regenerating damaged tissues and organs or replacing dysfunctional and dead cells.

There are already promising potential applications in chronic diseases, such as cancer, and metabolic diseases like diabetes and age-related macular degeneration. In future, stem cells could be used to alleviate currently untreatable conditions like dementia, fertility, and spinal cord injury.

Stem cell biology is complex and unpredictable, and producing pure, viable populations of stem cell derivatives at clinical scale can be slow and challenging.

In fact, 84% of cell therapy assets fail within two years of development, and 47% of cell therapy assets still fail after the five-year point in development.

CellVoyants platform combines advanced AI with live cell imaging to address these concerns.

Its technology can extract spatial and temporal information in real-time from hundreds of millions of cells within complex cell mixtures, helping scientists understand their composition and forecast how they will evolve.

This allows them to forecast stem cell behaviour with unprecedented precision and find optimal pathways for differentiating cells into specific cell types, such as nerve, cardiac or blood, facilitating more effective development of cell therapies.

According to the company, its technology can improve target cell yields, reduce time, and can offer potential savings of $10 100 million per therapy.

Uzma Choudry, Lead Biotech Investor at Octopus Ventures, added: University spin-outs like CellVoyant are at the heart of the UKs thriving biotech ecosystem. CellVoyant sets a new standard in precision and reliability for predicting and controlling stem cell behaviour, which will make cell therapies more accessible to those who need them. We are thrilled to invest into a company that is transforming how patients can benefit from life-changing treatments.

Originally posted here:
CellVoyant secures 7.6 million seed funding to develop stem cell therapies with AI - BioPharma-Reporter.com

Cell Therapy Technologies Market Projected to Reach Valuation of USD 47.3 Billion at 24.7% CAGR from 2024-2033 … – GlobeNewswire

New York, Jan. 16, 2024 (GLOBE NEWSWIRE) -- In 2023Cell therapy technologiesmarket were valued at USD 5.5 billion in 2023 with significant growth and are projected to reach USD 47.3 billion by 2033 with an outstanding CAGR of 24.7%.

The surge in demand for advanced diagnostic tools and therapeutic interventions is pushing the cell therapy technology market forward. Cell therapy, a main element in treating regenerative medicines, has become extensively popular, particularly in regenerative medicine. Combined with other equipment like Platelet-Rich plasma (PRP), cell therapy improves its power and effectiveness, proposing extra benefits to patients.

Get additional highlights on major revenue-generating segments, Request a Cell Therapy Technologies Market sample report at https://marketresearch.biz/report/cell-therapy-technologies-market/request-sample/

Cell therapy comprises launching innovative, healthy cells into a patient's body, playing a vital role in handling certain cancers and neurological diseases such as Parkinson's, amyotrophic lateral sclerosis (ALS), and diabetes. With over 1 million individuals worldwide suffering from Parkinson's disease, a number projected to reach 1.2 million by 2030, cell therapy emerges as a promising solution. Likewise, ALS is predominant, mostly in Western Europe, where it has a prevalence rate of 9.62 per 1,000,000 populations.

The benefits of cell therapy technologies comprise pain reduction, augmented functionality, fast-tracked recovery, aid in complex injuries, and a reduced risk of nerve damage and communicable diseases. As these therapies display innovative diagnostic and treatment methods, the market is poised for rapid expansion to meet the cumulative requirement for transformative medical solutions during the forecasted period.

Key Takeaways

Driving Factors

Introduction of Innovative Products

These innovative products, crafted to meet the requirements of different patients, have been instrumental in the advancement of cell therapies. This trend of continual product innovation is essential for keeping pace with the evolving demands of healthcare, ensuring the market's resilience and adaptability. The focus on innovation drives market growth by providing more effective, efficient, and tailored treatment options, thereby enhancing patient outcomes and expanding the potential applications of cell therapies. The market is composed of unrelenting growth, reinforced by a pipeline of advanced transformative cell therapy technologies.

Enhanced Demographic and Environmental Dynamics

Population growth escalates the demand for innovative healthcare solutions, including cell therapies for diverse medical conditions. Climate change, influencing disease patterns and health vulnerabilities, further propels the need for advanced treatments. These key factors collectively drive the development and adoption of cell therapy technologies, as they offer targeted and efficient treatment options for an array of health issues emerging in this changing global landscape.

To understand how our report can bring a difference to your business strategy, Inquire about a brochure at https://marketresearch.biz/report/cell-therapy-technologies-market/#inquiry

Restraining Factors

Cost and Reimbursement Issues

Cell therapy treatments are typically associated with high costs, both in terms of production and administration. The problem of reimbursement and costs is crucial to the development of the cell-based therapy business. Furthermore, the lack of clear reimbursement pathways adds to the complexity as insurers grapple with how to classify and cover these novel treatments. This makes them financially out of reach for many patients and healthcare systems. These financial hurdles not only limit patient access but also deter investment and innovation in the field, as developers and benefactors face vagueness about the return on their significant funds in these advanced therapies.

Growth Opportunities

Increased Interest in customized medicines

Personalized medicine's approach of tailoring treatments to individual patients aligns perfectly with the capabilities of cell therapies. These therapies' adaptability to patient-specific needs positions them at the forefront of innovative treatments for a variety of medical conditions. This illustrates the growing significance of technology in the realm of personalized healthcare in the upcoming era of cell therapy. As healthcare continues to evolve towards more personalized strategies, the demand for cell therapy technologies is expected to rise, bolstered by their potential to provide targeted, patient-specific treatments.

Have Queries? Speak to an expert or To Download/Request a Sample, Click here.

Regional Analysis

North America rules the cell therapy technologies market, holding 55.60% due to robust research infrastructure, substantial biotech investments, and favorable policies. The U.S. leads with ground-breaking biotech firms and supportive government initiatives. Europe, compelled by research and regulatory support, sees contributions from Germany, the UK, and France. In Asia-Pacific, prompt market growth results from augmented healthcare investments and biomedical research, particularly in Japan and South Korea. The region's large population and rising chronic diseases present substantial opportunities for expanding cell therapy technologies.

Segment Analysis

By therapy type, Autologous therapies rule the market segment due to their substantial role in treatments utilizing cells. This method is widely used in various treatments, including certain types of cancer therapies, where patients' cells are engineered to fight cancer cells more effectively. Through the use of donors' cells, allogeneic therapies can play a significant role in treatments utilizing cells. The most significant benefit of autologous treatment is that there is less possibility that the immune system will reject it and related complications since the cells are derived from patients themselves. These therapies have the advantage of being available off-the-shelf, making them more accessible and sometimes more cost-effective.

By cell type, stem cells dominate the market segment due to their extensive use in hematopoietic stem cell transplantation for blood and bone marrow disorders. Stem cells ability to differentiate into various cell types makes them incredibly valuable in regenerative medicine and the treatment of various diseases. Adipose-derived stem cells are being explored for their potential in regenerative therapies due to their abundance and ease of extraction. Non-stem cell therapies, while not as adaptable as stem cells, are important in precise therapeutic applications, predominantly in certain types of cancer treatments where immune cells are contrived to target cancer cells.

By cell therapy therapeutic area type, oncology leads the market segment due to the effectiveness of cell therapy in treating various types of cancers, particularly through approaches like CAR-T cell therapies, which have transformed cancer treatment. These therapies have shown remarkable results in certain types of blood cancer, leading to significant investment and research in expanding their application to other cancer types. In dermatology, cell therapies offer advanced treatment options for skin regeneration and healing. Other therapeutic areas like cardiovascular disease (CVD), musculoskeletal disorders, dermatology, and others are also significant. Cell therapies in CVD aim to regenerate damaged heart tissue, while in musculoskeletal disorders, they are used for tissue repair and pain management.

For more insights on the historical and Forecast market data from 2016 to 2033 - download a sample report at https://marketresearch.biz/report/cell-therapy-technologies-market/request-sample/

Segments Covered in this Report

By Therapy Type

By Cell Type

By Cell Therapy Therapeutic Area

By Geography

Grow your profit margin with Marketresearch.biz - Purchase This Premium Report at https://marketresearch.biz/purchase-report/?report_id=8948

Competitive Landscape Analysis

In the dynamic field of cell therapy technologies, industry front-runners such as Thermo Fisher Scientific, Danaher Corporation, Becton, Dickinson & Company, Merck KGaA, Lonza Group, Sartorius AG, FUJIFILM Irvine Scientific, and Avantor, Inc. play pivotal roles. Their inclusive product ranges and tactical focuses on innovation, accuracy, and amalgamation contribute significantly to advancing cell therapy research, manufacturing, and efficiency.

Key Market Players

Recent Developments

Browse More Related Reports

About Us:

MarketResearch.Biz (Powered by Prudour Pvt Ltd) specializes in in-depth market research and analysis and has been proving its mettle as a consulting and customized market research company, apart from being a much sought-after syndicated market research report-providing firm.MarketResearch.Bizprovides customization to suit any specific or unique requirement and tailor-made reports as per request. We go beyond boundaries to take analytics, analysis, study, and outlook to newer heights and broader horizons.

Follow Us on LinkedIn:https://www.linkedin.com/company/marketresearch-biz/ Follow Us on Facebook:https://www.facebook.com/marketresearch.biz Follow Us on Twitter:https://twitter.com/PrudourResearch

Here is the original post:
Cell Therapy Technologies Market Projected to Reach Valuation of USD 47.3 Billion at 24.7% CAGR from 2024-2033 ... - GlobeNewswire

Researchers genetically modify stem cells to evade immunological rejection – University of Arizona

One of the biggest barriers to regenerative medicine is immunological rejection by the recipient, a problem researchers at the University of Arizona Health Sciences are one step closer to solving after genetically modifying pluripotent stem cells to evade immune recognition. The study Engineering Human Pluripotent Stem Cell Lines to Evade Xenogeneic Transplantation Barriers waspublished in Stem Cell Reports today.

Pluripotent stem cells can turn into any type of cell in the body. The findings offer a viable path forward for pluripotent stem cell-based therapies to restore tissues that are lost in diseases such as Type 1 diabetes or macular degeneration.

There has been a lot of excitement for decades around the field of pluripotent stem cells and regenerative medicine, said principal investigator Deepta Bhattacharya, PhD, a professor in the UArizona College of Medicine Tucsons Department of Immunobiology. What we have learned from the experiences of organ transplantation is that you have to have matched donors, but the person receiving the transplant often still requires lifelong immune suppression, and that means there is increased susceptibility to infections and cancer. Weve been trying to figure out what it is that you need to do to those stem cells to keep them from getting rejected, and it looks like we have a possible solution.

To test their hypothesis, Bhattacharya and the research team used CRISPR-Cas9 technology, genetic scissors that allow scientists to make precise mutations within the genome at extremely specific locations.

Using human pluripotent stem cells, the team located the specific genes they believed were involved in immune rejection and removed them. Prior research into pluripotent stem cells and immune rejection looked at different parts of the immune system in isolation. Bhattacharya and his colleagues from The New York Stem Cell Foundation Research Institute, St. Jude Childrens Research Hospital and the Washington University School of Medicine opted to test their genetically modified stem cells in a complete and functional immune system.

The immune system is really complicated and there are all sorts of ways it can recognize and reject things, said Bhattacharya, a member of the UArizona Cancer Center and the BIO5 Institute who also serves on the UArizona Health Sciences Center for Advanced Molecular and Immunological Therapies advisory council.

Transplantation across species, across the xenogeneic barrier, is difficult and is a very high bar for transplantation. We decided if we could overcome that barrier, then we could start to have confidence that we can overcome what should be a simpler human-to-human barrier, and so thats basically what we did.

The research team tested the modified stem cells by placing them into mice with normal, fully functioning immune systems. The results were promising the genetically engineered pluripotent stem cells were integrated and persisted without being rejected.

That has been the holy grail for a while. You might actually have a chance of being able to perform pluripotent stem cell-based transplants without immune suppressing the person who is receiving them. That would be an important advance, both clinically and from the simple standpoint of scale, Bhattacharya said. You wouldnt have to make individualized therapies for every single person you can start with one pluripotent stem cell type, turn it into the cell type you want and then give it to almost anyone.

The next steps, Bhattacharya said, include testing the genetically modified pluripotent stem cells in specific disease models. He is already working with collaborators at The New York Stem Cell Foundation and the Juvenile Diabetes Research Foundation to test the technology in animal models for Type 1 diabetes.

We needed to overcome the immune system first. The next steps are how do we use these cells? Bhattacharya said. We set the bar pretty high for our study and the fact that we were successful gives us some confidence that this can really work.

Bhattacharya also is the co-founder of startup Clade Therapeutics in Boston, which licensed the technology through Tech Launch Arizona, the University of Arizonas commercialization arm. Clade Therapeutics is establishing a robust cellular platform using stem cell-derived immune cells for the treatment of cancer and autoimmune diseases. The company said it hopes to begin clinical trials by the end of the year.

Co-authors on the paper include: Hannah Pizzato, PhD, research specialist in the College of Medicine Tucsons Department of Immunobiology; Paula Alonso-Guallart, DVM, PhD, James Woods and Frederick J. Monsma Jr., PhD, of The New York Stem Cell Foundation Research Institute; Jon P. Connelly, PhD, and Shondra M. Pruett-Miller, PhD, of the St. Jude Childrens Research Hospital; and Todd A. Fehniger, MD, PhD, and John P. Atkinson, MD, of the Washington University School of Medicine.

Read this article:
Researchers genetically modify stem cells to evade immunological rejection - University of Arizona

Sarah Irvine’s Battle with MS: The Hope of Stem Cell Treatment – BNN Breaking

Sarah Irvines Battle with MS: The Hope of Stem Cell Treatment

On a quiet street in a bustling city, Sarah Irvine lives a life that is far from ordinary. Diagnosed with a progressive form of multiple sclerosis (MS) in 2019, she faces a daily battle against her own body. In the midst of the turmoil, Sarah, like a beacon of resilience, is aspiring to undergo stem cell treatment in London, a decision that could potentially change the course of her life.

Multiple sclerosis is a debilitating condition where the immune system, in an uncharacteristic act of betrayal, turns against the nerve cells in the brain, spinal cord, and optic nerves. This internal assault can lead to severe impairments in mobility and other neurological functions, trapping individuals in a body that refuses to obey.

For Sarah, this is more than just medical jargon. Its her reality. Every day, she wakes up to a world where simple tasks become Herculean challenges and where the uncertainty of the future looms large. Yet, in the face of adversity, she stands undeterred, ready to fight.

In her quest to combat the impact of this disease, Sarah is setting her sights on a treatment that, while often seen as a last resort, holds the promise of potentially slowing down, or even halting, the progression of her MS symptoms. This treatment involves the transplantation of stem cells, tiny powerhouses of regeneration that may hold the key to resetting the immune system and halting its attack on the nervous system.

Sarahs journey is far from easy. The road to potential treatment is fraught with obstacles, each more daunting than the last. But her determination is unwavering. In her struggle, she becomes a symbol of resilience, a testament to the human spirits indomitable will to survive.

As Sarah navigates her path towards potential recovery, her story serves as a reminder of the ongoing struggle faced by individuals living with MS and the relentless search for effective therapies. In the midst of the battle, however, one thing remains clear: the spirit of the human will, as embodied by Sarah, remains unbroken, undeterred, and unstoppable.

Read more here:
Sarah Irvine's Battle with MS: The Hope of Stem Cell Treatment - BNN Breaking

Life Science Research Heads to the ISS on Axiom Mission 3 – ISS National Lab

KENNEDY SPACE CENTER (FL), January 10, 2024 More than two dozen investigations sponsored by the International Space Station (ISS) National Laboratory, many of which focus on the life sciences, will fly on Axiom Spaces third private astronaut mission to the orbiting laboratory. Axiom Mission 3 (Ax-3) aims to help expand a new era of privatized utilization of the space station that will bring value to humanity while enabling the development of a robust and sustainable market in low Earth orbit (LEO) by advancing research in microgravity.

Four astronauts are slated to launch on a SpaceX Falcon 9 rocket and Dragon spacecraft to the space station no earlier than Wednesday, January 17, at 5:11 p.m. EST from NASAs Kennedy Space Center in Florida. During a planned two-week mission, Axiom Spaces chief astronaut and former NASA astronaut Michael Lpez-Alegra (commander), Walter Villadei of Italy (pilot), Alper Gezeravc of Trkiye (mission specialist), and European Space Agency (ESA) project astronaut Marcus Wandt of Sweden (mission specialist) will conduct more than 30 experiments.

Building on years of foundational research performed in microgravity, a number of these investigations aim to utilize the unique LEO environment to better understand an array of biological processes, including how spaceflight affects the human body, the mechanisms behind certain diseases, and how stem cell research can help lead to the development of novel therapeutics.

Below are some highlights of the investigations launching on the Ax-3 mission:

Through these private astronaut missions, Axiom Space and the ISS National Lab partner to expand access to the unique microgravity environment for the benefit of humanity. Ax-3 represents the first all-European commercial mission to the space station, further expanding spaceflight opportunities to more countries, companies, and people. In addition to the projects highlighted above, Ax-3 includes a strong focus on the scientific portfolios of the European nations represented on this mission, seeking to enhance scientific knowledge gained for humanity.

Read more about these investigations and others launching on this mission in Axiom Spaces Research Overview and on the ISS National Lab Ax-3 launch page.

Download the high-resolution image for this release: Axiom-2 Launch

Media Contact: Patrick ONeill 904-806-0035 PONeill@ISSNationalLab.org

# # #

About the International Space Station (ISS) National Laboratory: The International Space Station (ISS) is a one-of-a-kind laboratory that enables research and technology development not possible on Earth. As a public service enterprise, the ISS National Laboratory allows researchers to leverage this multiuser facility to improve quality of life on Earth, mature space-based business models, advance science literacy in the future workforce, and expand a sustainable and scalable market in low Earth orbit. Through this orbiting national laboratory, research resources on the ISS are available to support non-NASA science, technology, and education initiatives from U.S. government agencies, academic institutions, and the private sector. The Center for the Advancement of Science in Space (CASIS) manages the ISS National Lab, under Cooperative Agreement with NASA, facilitating access to its permanent microgravity research environment, a powerful vantage point in low Earth orbit, and the extreme and varied conditions of space. To learn more about the ISS National Lab, visit our website.

As a 501(c)(3) nonprofit organization, CASIS accepts corporate and individual donations to help advance science in space for the benefit of humanity. For more information, visit our donations page.

About Axiom Space: Axiom Space is building for beyond, guided by the vision of a thriving home in space that benefits every human, everywhere. The leading provider of human spaceflight services and developer of human-rated space infrastructure, Axiom Space operates end-to-end missions to the International Space Station today while developing its successor, Axiom Station the worlds first commercial space station in low-Earth orbit, which will sustain human growth off the planet and bring untold benefits back home. For more information visit Axiom Spaces website.

Read the original post:
Life Science Research Heads to the ISS on Axiom Mission 3 - ISS National Lab

A guide to stem cell therapy in Thailand – Thaiger

PHOTO: Stem Cell Therapy at Identity Clinic

You probably have heard about stem cell therapy and its ability to improve your quality of life and feel sceptical about it. While the procedure may sound like something out of science fiction, its actually a promising medical procedure with a wide range of benefits. In fact, it has grown in popularity and shown remarkable effectiveness over the past few years. Thailand has been quick to adapt stem cell therapy and is now leading the charge in Asia.

If youre thinking about getting stem cell therapy in Thailand, you probably have a lot of questions about it. What exactly is it? Is it the appropriate procedure for your condition? Can it really reverse ageing? Where should you head to in Thailand to receive this treatment? To answer some of your questions, we sat down with Dr. Puii and Josh from Identity Clinic Bangkok to get an insight into stem cell therapy in Thailand.

Before we go into details on stem cell therapy in Thailand, lets first talk about the basics.

Stem cell therapy is a newer medical procedure that uses the power of stem cells, which are unspecialized cells that provide new cells for your body as you grow, and replace specialised cells that are damaged or lost. Were born with these cells and they continue to multiply until we reach the age of around 20. After that, though, their numbers and effectiveness start to decline. At around the age of 30 to 35 years old, they take a significant dip in both quality and quantity. This reduction in stem cells is one reason why our bodies start showing signs of ageing.

Stem cells play a crucial role in our health, helping with growth, repair, and even tackling inflammation. Thats why stem cell therapy is a promising medical procedure to treat various medical conditions.

Stem cell therapy provides a wide range of benefits. While it can be used to treat a range of health conditions, stem cell therapy also makes its way into cosmetic treatments and wellness initiatives. Here are some of the main benefits of stem cell therapy that you can get in Identity Clinic Bangkok, Thailand:

Stem cell therapy offers a wide range of benefits for those seeking enhanced well-being.

One of the most popular benefits of stem cell therapy is skin rejuvenation. The therapy facilitates the healing of bruises, cuts, and other skin imperfections. In addition, it can also reduce wrinkles and increase the strength of your dermis the thick layer of living tissue that forms your true skin beneath the epidermis. Stem cell therapy restores the skin deep down to the cellular level, causing your skin to become brighter and tighter. Thus, youll feel refreshed and rejuvenated after each treatment.

In addition to enhancing your immune system, this cutting-edge treatment can also positively impact your sleep quality, which in turn will boost your overall energy levels. Research by DVC Stem reveals that patients undergoing stem cell therapy have reported impressive results, with a notable 75% increase in stamina and a significant 51.40% improvement in energy levels 3 months after treatment.

Stem cell therapy can improve your cognitive function, such as memory and decision-making abilities. Plus, it can make a big difference in how well your nerves send signals to your muscles, which means it can enhance your motor functions.

Youd be amazed to know how much your blood work can benefit from consistent stem cell therapy. Over time, this can also boost the performance of your kidneys and liver, and generally enhance the health of all your organs.

Stem cell therapy in Identity Clinic Bangkok, Thailand can also be used as targeted treatment for specific conditions.

If youve been dealing with knee pain, stem cell therapy may be able to regenerate your knee joints due to arthritis, traumatic ligament injuries, and degenerative conditions.

Stem cell therapy has shown promise in slowing down dementia, such as Alzheimers disease. This is achieved by substituting impaired cells with robust ones, enhancing memory functionality, and regenerating neurons.

Erectile dysfunction, the inability to keep an erection, can be treated with stem cell therapy. With this therapy, the stem cells act as a muscle inside the penis, thereby rejuvenating its tissues and restoring their functionality.

Stem cell therapy is a breakthrough in the treatment of Crohns disease. It has the potential to lessen intestinal inflammation, foster the recovery of the intestinal lining, and enhance your overall life quality.

According to Dr. Puii, another significant benefit of stem cell therapy is helping individuals with pathological conditions like diabetes, hypertension, and heart conditions. Stem cell therapy becomes a continuous treatment option for those seeking to improve and manage their conditions.

Beyond adult treatments, stem cell therapy shows promise in treating chronic diseases in children, such as cerebral palsy, mental disorders, and movement abnormalities. The therapy offers hope for improving conditions that persist into adulthood.

If youve been reading about stem cell therapy, youre probably aware that there are misconceptions surrounding it, causing confusion and fear. One prevalent misconception suggests that stem cell therapy can increase your risk of cancer. There have been no reports of the therapy causing cancer, but to mitigate potential risks, its essential to get this treatment from trusted clinics that use approved stem cells.

Another misconception about stem cells is that they may lead to the growth of extra limbs. Its crucial to clarify that such fantastical claims lack scientific basis. Stem cell therapy, when administered responsibly, adheres to stringent safety standards and does not result in abnormal cell proliferation or limb regeneration.

Its important to remember that while stem cell therapy isnt a universal solution, its not a harmful procedure. Stem cell therapy doesnt reverse ageing or prompt the growth of additional body parts. Instead, its focus is on aiding the bodys natural healing processes and enhancing overall well-being.

There are many medical centres across Thailand offering stem cell therapy, but not all of them are the same. Just like any other healthcare procedure, the most important thing when it comes to stem cell therapy is choosing the right clinic. Be sure to verify that the doctors and staff are well-versed in the procedure and that the clinic is committed to advancing their stem cell therapy technology, This ensures you receive the best possible treatment with a high success rate.

One of the leading clinics offering stem cell therapy in Thailand is Identity Clinic. With top-notch stem cell banks, world-class laboratories, and VIP rooms, the clinic ensures clients receive a royal and unmatched experience. Heres what Identity Clinic offers to their patients:

What sets Identity Clinic apart is its commitment to high-quality stem cells. They use Mesenchymal Stem Cells (MSCs) from the umbilical cord that are carefully screened for health conditions by world-class certified labs and the US FDA. Moreover, these stem cells come with extensive certifications, blood work, and detailed reports. The clinic uses an ID Barcode system to ensure accuracy and traceability. Therefore, clients have full transparency about the stem cells they receive.

Identity Clinic boasts certifications from esteemed global institutions. These include the American Association of Blood Banks (AABB) standards, a recognition highly esteemed by medical organisations worldwide, particularly those in the United States. The clinic also holds the ISO 9001 certification and uses US FDA-approved medical equipment to provide the best and safest procedures for their patients. Furthermore, the clinic has been honoured with the European Society for Quality Research award from Germany, a prestigious recognition given to organisations that demonstrate exceptional quality and ethical practices.

Patients at Identity Clinic enjoy a luxurious and comfortable experience. From the customer service to the interior, the clinic ensures a premium healthcare journey. The staff goes the extra mile to meet all of your needs. Moreover, the treatment rooms are designed to promote both physical comfort and peace of mind as you undergo stem cell therapy.

Identity Clinic takes pride in staying at the forefront of stem cell research and therapy. The dedicated team, led by renowned doctors like Dr. Shin and Dr. Puii, continuously studies and integrates the latest advancements in stem cell treatment.

Stem cell therapy can work wonders in addressing a wide range of medical conditions. And Identity Clinic is dedicated to offering stem cell therapies for all kinds of patients, including those seeking skin rejuvenation. They combine stem cell therapy with state-of-the-art skin treatments like laser procedures and Thermage. This integrated approach not only enhances overall health but also greatly improves skin texture and appearance, adding a youthful glow like never before.

At Identity Clinic, stem cell therapy is not a one-size-fits-all treatment. They offer personalised care plans for various health conditions to make sure that every patient receives positive and sustained effects from their stem cell therapy. To achieve this, they perform a series of preliminary medical evaluations on every new patient prior to beginning their treatment. Among these tests, checking for allergies and carrying out comprehensive assessments for potential underlying medical conditions are essential parts of their preparation protocol.

If youre curious about the potential benefits of stem cell therapy, be sure to contact Identity Clinic for more information. With a focus on quality, certifications, and personalised care plans, the clinic ensures a top-notch experience for every patient.

Sponsored

See the original post:
A guide to stem cell therapy in Thailand - Thaiger

Majority Leader Scalise to miss all of January as he undergoes stem cell treatment – Washington Examiner

House Majority Leader Steve Scalise (R-LA) will not return to Washington, D.C., until February as he undergoes a stem cell transplant as part of his cancer treatment, his office announced on Friday.

Last year, Scalise was diagnosed with multiple myeloma and underwent chemotherapy, which he completed in December. According to his office, Scalise had a positive response to the treatment and became eligible for an autologous stem cell transplant.

GOP TO PRESS FAUCI ON HANDLING OF SCIENTIFIC DEBATE IN FIRST POST-RETIREMENT TESTIMONY

He is currently undergoing the transplant process, marking a significant milestone in his battle against cancer. Once the procedure is completed, he will be recovering under the supervision of his medical team and will work remotely until returning to Washington next month. He is incredibly grateful to have progressed so well, and is thankful to his entire medical team, family, friends, and colleagues for their prayers and support, his office said in a statement.

With Scalise being gone for the month of January, it further dwindles House Republicans already slim majority during a month in which they are faced with a battle over must-pass legislation.

CLICK HERE TO READ MORE FROM THE WASHINGTON EXAMINER

When the House returns on Jan. 9, lawmakers will immediately be tasked with passing government funding, some of which will expire on Jan. 19.

Currently, House Republicans have a 220-seat majority. That will drop to 219 with Scalise gone and 218 when Rep. Bill Johnson (R-OH) leaves on Jan. 21. This will make it that much harder for leadership to pass legislation, which it was already struggling to get through the lower chamber.

Excerpt from:
Majority Leader Scalise to miss all of January as he undergoes stem cell treatment - Washington Examiner

Global Stem Cell Therapy Market to Reach Value of USD 26.15 Billion by 2030 | Skyquest Technology – GlobeNewswire

Westford,USA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- According to SkyQuest report, the global stem cell therapy market is experiencing substantial growth, primarily propelled by the increasing burden of chronic diseases such as cardiovascular disorders, neurodegenerative conditions, and orthopedic injuries. These debilitating ailments have placed a significant strain on healthcare systems worldwide.

Get sample copy of this report:

https://www.skyquestt.com/sample-request/stem-cell-therapy-market

Browse in-depth TOC on the "Stem Cell Therapy Market"

The field of stem cell research has undergone a remarkable transformation driven by significant advances in technology and scientific understanding. These breakthroughs have broadened our knowledge of stem cells and expanded their potential applications in the global stem cell therapy market. Innovative methods for isolating, growing, and differentiating stem cells have been developed, facilitating their use in various therapeutic environments.

Report Scope & Segmentation:

Browse summary of the report and Complete Table of Contents (ToC):

https://www.skyquestt.com/report/stem-cell-therapy-market

Prominent Players in Global Stem Cell Therapy Market

Allogeneic Therapy Segment is Expected to Rise Significantly due to Increasing Popularity of Stem Cell Banking

Allogeneic therapy segment has emerged as the dominant force in the stem cell therapy market, commanding a substantial market share of 59.14% in 2022. This remarkable growth can be attributed to several key factors. Firstly, allogeneic therapies often come with higher pricing, contributing significantly to revenue generation. Moreover, the increasing popularity of stem cell banking, which involves collecting and storing allogeneic stem cells for potential future use, has driven demand for these therapies.

The market in North America has firmly established its dominance in the stem cell therapy market, commanding the largest revenue share at 44.56% in 2022. One key driver is the presence of innovative companies and major regional market players. North America is home to a robust and dynamic biotechnology and pharmaceutical industry, fostering stem cell therapy product development, production, and commercialization.

Autologous Therapy Segment is Expected to Dominate Market Due to Lower Risk of Complications

Autologous therapy segment is poised to experience significant growth over the forecast period, and several key factors contribute to this trajectory in the stem cell therapy market. One primary driver is the lower risk of complications associated with autologous treatments, as these therapies utilize a patient's stem cells, minimizing the chances of immune rejection or adverse reactions. Additionally, autologous therapies are often more affordable and accessible for patients, making them attractive.

Regional market in the Asia Pacific region is poised to become a significant growth driver in the stem cell therapy market, with a projected CAGR of 16.09% expected from 2023 to 2030. The region boasts a robust product pipeline of stem cell-based therapies, with ongoing research and development initiatives driving innovation.

A comprehensive analysis of the major players in the stem cell therapy market has been recently conducted. The report encompasses various aspects of the market, including collaborations, mergers, innovative business policies, and strategies, providing valuable insights into key trends and breakthroughs in the market. Furthermore, the report scrutinizes the market share of the top segments and presents a detailed geographic analysis. Lastly, the report highlights the major players in the industry and their endeavors to develop innovative solutions to cater to the growing demand.

Key Developments in Stem Cell Therapy Market

Speak to Analyst for your custom requirements:

https://www.skyquestt.com/speak-with-analyst/stem-cell-therapy-market

Key Questions Answered in the Stem Cell Therapy Market Report

Related Reports in SkyQuests Library:

Global Protein Therapeutics Market

Global Chemiluminescence Immunoassay Analyzers Market

Global Biobanking Market

Global Epigenetics Market

Global Microplate Reader Market

About Us:

SkyQuest Technologyis leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.

Address:

1 Apache Way, Westford, Massachusetts 01886

Phone:

USA (+1) 617-230-0741

Email:sales@skyquestt.com

LinkedInFacebookTwitter

More:
Global Stem Cell Therapy Market to Reach Value of USD 26.15 Billion by 2030 | Skyquest Technology - GlobeNewswire

Choosing the Right Excipients for MSC and iPSC Therapies – Pharmaceutical Technology Magazine

Buffers, stabilizers, and cryoprotectants play major roles in cell therapy formulations.

While many stem-cell therapies remain at the preclinical stage, several are progressing through the clinic toward late-stage trials. Developing successful treatments based on induced pluripotent stem cells (iPSCs) and mesenchymal stem cells (MSCs) in part depends on creating effective formulations in which cell viability is maintained during cryopreservation, storage and handling, shipment, and reconstitution prior to delivery to the patient. Excipients, therefore, play an important role in bringing novel cell therapies to the market.

As with most biologic drug products, the predominant excipient in cell therapy formulations is the buffered saline solution. In this case, the saline solution is an osmotically balanced water solution designed to keep the cells from drying out and dying, according to Ryan Guest, senior CMC translation consultant for eXmoor pharma.

In addition to physiological saline, Carole Nicco, CSO at BioSenic notes that other isotonic solutions containing chemical substances present in blood, such as Ringers lactate, are also used to help maintain the electrolyte balance and keep the cells stable, sterile, and viable with proliferative capacity until their application. Furthermore, these isotonic solutions offer chemical easy systemic and local application, according to Nicco.

Classically, most formulations will also have protein to balance the solution as a buffer or reservoir for smaller molecules and enable transport via active protein transporters on cell membranes, Guest notes. The standard is an albumin (0.52.5%), such as human serum albumin. Albumin constitutes 5075% of the colloidal osmotic pressure of blood (13) and performs a very similar role in MSC and iPSC formulations, Guest says. More specifically, albumin is a useful component in cell therapy formulations for balancing water availability during product hold times, cryopreservation, and thawing prior to product administration.

In fact, Guest observes that the presence of an equivalent protein in cell therapy formulations is predicted to have a significant impact on cell survival. In MSCs, for instance, the absence of an appropriate protein can reduce viable recovery by 2040%, he comments.

The other important excipients for cell therapy products are cryoprotectants, given that the majority of these treatments are cropreserved. The cryopreservation of MSC- and iPSC-based therapies using 210% dimethyl sulfoxide (DMSO) in solutions containing ahigh content ofserum is a common procedure, Nicco observes. She adds that while DMSO has been used to reduce the formation of ice in cells stored in liquid nitrogen since 1959, it is toxic, resulting in undesired clinical and biological side effects. Serum also introduces variation and safety risks.

There is, consequently, Nicco says, a move toward solutions containing bio-preservation media free of DMSO, serum, and other proteins, optimized for the preservation and distribution of these products at low temperatures, either in cold (28 C) or cryopreserved conditions (-70 C to -196 C). The new excipients, she explains, eliminate toxicity issues as well as the need for human product excipients (serums, proteins) that can induce a risk of contamination to the drug product. Complex formulations involving dextran-40, lactobionate, sucrose, mannitol, glucose, adenosine, and/or glutathione are examples, according to Guest.

The type of stem cell therapy generally does not impact the choice of excipients, although Guest does note that some iPSCs can be more acutely sensitive to the final formulation, hold times, and routes of administration. For example, anucleated products, specifically designed to deliver payloads, have a reduced capability to produce proteins or perform cellular repair. Nicco adds that iPSCs and cells differentiated from them are commonly multicellular systems, which she says also makes them more sensitive to the stresses of freezing and thawing than single cells.

Overall, however, similar types of excipients are used for the preservation of cell-based therapies, regardless of the cell type or method of manipulation, according to Nicco. It is the route of administration, the need for transport, and the storage temperature that influence the choice of excipients, she states.

Special applications, for instance, such as therapies for artificial skins and wound healing may have specific properties or additional ingredients for sealing the wounds, Guest notes. Hence, the excipients or scaffolds are part of these therapies. Dosage size is another important factor, he adds. Larger doses need to take into account any toxic side effects of the excipients, such as DMSO, and may place maximal limits upon the total volume of excipients to be administered, he observes.

One of the most critical issues for cell therapy manufacturers is the maintenance of the cells in an appropriate medium/excipient from the end of the culture until the time of administration to the patient. Not only should the medium keep the cells viable with their properties intact, but the route of administration must also be taken into account, Nicco states. She adds that a good excipient is solvent-free and suitable for fresh or frozen suspensions of living cells formulated in a proprietary formulation adapted to the route of administration, such as intravenous, intra-articular, or intracranial.

In addition to understanding the delivery mechanism, Guest stresses the importance of considering the container and dose when choosing excipients. The next important factor, he says, is whether the cell therapy product will be supplied frozen, as that will require selection of a cryoprotectant. Formulation development experiments should then be designed carefully to optimize potency while taking into consideration hold periods and freeze/thaw steps and eliminating or otherwise minimizing the use of diluents and wash steps. In addition, Guest recommends evaluating existing administration formulations, containers, equipment, and protocols to minimize the need for new or changes to clinical practices.

An important component of any formulation strategy is consideration of the raw materials.For excipients intended for use in cell therapy products, Guest emphasizes the need to identify available good manufacturing practice (GMP)-suitable sources with acceptable lot-to-lot controls that will enable a reproducible product formulation. It is also critical, he says, to confirm the material is suitable for the manufacturing process and will be available to meet manufacturing demand for the cell therapy throughout its product life cycle.

Equally important, Guest observes, is to ensure the availability of suitable cellular material and drug product for designing formulation experiments. Understanding the patient group and the intended administration route are essential, meanwhile, for identifying potential side effects of any excipients.

Compendial excipients are generally preferred, Guest continues, due to the risk that novel or untested solutions will require significant development to ensure the material does not impact upon the therapeutic benefit of the cellular material. In addition, all materials including excipients must be suitable for the intended route of administration and present minimal risk of inducing toxicity, immune reactions, or the transfer of adventitious agents.

Controlling cellular material from the point of optimal donor selection to manufacturing under GMP conditions, commercialization, and application is critical for ensuring the quality, safety, and efficacy of the final drug product. While MSCs used as starting materials for production of advanced therapy medicinal products can only be isolated in authorized centers using globally standardized processes, the optimal conditions for culturing isolated MSCs are not standardized. That poses a major challenge in controlling their quality and therapeutic properties, Nicco contends.

It is, therefore, essential to control the cell sources (e.g., bone marrow, umbilical cord, and adipose tissue), cell density in culture, duration of culture, and cell engineering and composition of culture media and implement in-process quality controls that ensure cell efficacy and safety at all stages of manual and automated manufacturing processes, including cryopreservation, use of cell banks, and transport systems. Ultimately, the stability and quality of the cell therapy product and the excipients it contains must always be evaluated against reference samples submitted to the same storage facility, emphasizes Nicco.

Complicating this situation is the fact that it can be difficult to find reliable mode-of-action potency methods for cell-based therapies, according to Guest. Often both in vitro cell culture and in vivo models are required to confirm the suitability of the formulation, he says.

In addition, formulation strategy, hold times, cryopreservation, and thawing are intrinsically linked, and it can be difficult to determine the impact of each component of the formulation, Guest observes. Doing so requires carefully designed experiments and suitable analytical methods that assess not only the impact of formulation changes and freezing and thawing processes, but downstream biological mechanisms such as apoptosis and necrosis, which require time in a suitable cell-culture facility or in vivo models to optimize formulations, he explains.

A further difficulty rests with the fact that viability determinations are often tied to the analytical methods, the technicians performing them, and whether biological mechanisms of apoptosis and true cell recoveries are accounted for in the testing strategy, Guest comments. Therefore, it is important for cell therapy developers relying on external testing laboratories to ensure those outsourcing partners have the proper understanding, expertise, and capabilities needed for appropriate and comprehensive testing.

The cell therapy field is expanding at a rapid rate, and technology is advancing to support the increasing breadth of treatments under development. That includes formulation science and the development of enhanced excipient solutions. Cryoprotectants developed through biomimicry of natural antifreeze proteins to replace DMSO and serum protein-based media are one example highlighted by Nicco.

More work is to be done in this area, however. There is a clear unmet need for the discovery and development of novel cryoprotectants that can either replace or reduce the required amounts of current gold standards formulated to protect and treat challenging sample types such as MSCs and, even more, iPSC multicellular systems. This multivariate problem is complex, with multiple mechanisms of damage to be addressed and subtle differences between cell types and freezing methods. Combining high-throughput testing with iterative computational algorithms is key to optimizing protocols and excipient formulations to preserve emerging cell-based therapies, Nicco comments.

Guest, meanwhile, predicts that as the cell therapy field advances, clinical practice will naturally standardize formulation, delivery, and routes of administration through product safety and efficacy data. That will include the use of animal-free or recombinant excipients and other fit-for-purpose additives developed through the use of artificial intelligence to minimize cytotoxicity while improving stability and hold times, he states.

Nicco is also confident that the combination of new technologies such as intelligent library design, computational modeling, rapid screening assays, and advances in genomics will lead to a better understanding of the structure-function relationships between drug and excipient. That greater understanding will lead to more effective and efficient excipients that afford higher-performing cell therapies and ultimately benefit both cell therapy developers and patients, she concludes.

Cynthia A. Challener, PhD, is a contributing editor to Pharmaceutical Technology.

Pharmaceutical Technology Vol. 48, No. 1 January 2024 Pages: 2021, 25

When referring to this article, please cite it as Challener, C.A. Choosing the Right Excipients for MSC and iPSC Therapies. Pharmaceutical Technology 2024 48 (1).

Read more from the original source:
Choosing the Right Excipients for MSC and iPSC Therapies - Pharmaceutical Technology Magazine

5 Medical Innovations from 2023 – Right as Rain by UW Medicine

Its never been a more exciting time for medical breakthroughs, from understanding mysterious conditions like post-COVID-19 to using everything from stem cell therapies to smartphones to advance health and well-being. Many of these innovations are happening right here in the Pacific Northwest by UW Medicine researchers.

We rounded up five of the most mouth-dropping medical developments that happened at UW Medicine in 2023.

Last December, Adriana Rodriguez, a 31-year-old from Bellingham, experienced a spontaneous tear in one of her coronary arteries two weeks after giving birth. While such tears can sometimes heal on their own, Rodriguezs heart was so damaged that it began to fail. She needed a transplant, but because of her recent pregnancy, her blood antibody levels were high, making it almost certain that her immune system would attack and reject a donor heart.

Dr. Shin Lin, a heart failure specialist, and Dr. Jay Pal, the heart transplant surgical director, made an unprecedented recommendation that she undergo a dual heart-liver transplantbased on a few reports of immunological protection in patients who had been transplanted with a liver and then a heart to replace two failing organs. Because the patients own liver was normal, the plan was to domino it into another patient who had end-stage liver disease.

On January 14, during a 17-hour procedure at UW Medical Center Montlake, Dr. Mark Sturdevant and Dr. Ramasamy Bakthavatsalam removed Rodriguezs healthy liver, transplanted her with the donor organ, and transplanted her liver into another patient who needed one. Next, Pal and Dr. John Dimarakis transplanted the donor heart. After 65 days, her antibody response to her new heart disappeared, ending the immediate threat of organ rejection.

We don't fully understand the science of transplant immunology, says Dr. Daniel Fishbein, a colleague at the Heart Institute. We need to understand the magic so we can hopefully, someday, repeat it with medications instead of an organ.

Researchers at the UW School of Medicine and UW School of Dentistry used stem cells to generate the proteins that create dental enamel, the stuff that protects teeth from getting damaged and prevents decay. They hope their findings could lead to a first-ever process to make new enamel for damaged teeth.

The body has no way to repair enamel: Specialized cells make the super hard tissue while teeth are growing, but those cells then die off when the teeth are fully formed. So a stem cell therapy to restore enamel while filling cavities, for example, would be a game-changer for repairing damaged teeth.

Hannele Ruohola-Baker, a professor of biochemistry and associate director of the UW Medicine Institute for Stem Cell and Regenerative Medicine, leads the lab that carried out this research in the Department of Biochemistry at the UW School of Medicine. She believes that one day, the findings could lead to living fillings, or fillings with stem cells that could reconstruct a broken or damaged tooth, or even a therapy that could grow a tooth back entirely.

It may take a while before we can regenerate them, but we can now see the steps we need to get there, Ruohola-Baker says.

Read more:
5 Medical Innovations from 2023 - Right as Rain by UW Medicine